Literature DB >> 8314024

Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes.

L S Wicker1, E H Leiter, J A Todd, R J Renjilian, E Peterson, P A Fischer, P L Podolin, M Zijlstra, R Jaenisch, L B Peterson.   

Abstract

The role of CD8+ T-cells in the development of diabetes in the nonobese diabetic (NOD) mouse remains controversial. Although it is widely agreed that class II-restricted CD4+ T-cells are essential for the development of diabetes in the NOD model, some studies have suggested that CD8+ T-cells are not required for beta-cell destruction. To assess the contribution of CD8+ T-cells to diabetes, we have developed a class of NOD mouse that lacks expression of beta 2-microglobulin (NOD-B2mnull). NOD-B2mnull mice, which lack both class I expression and CD8+ T-cells in the periphery, not only failed to develop diabetes but were completely devoid of insulitis. These results demonstrate an essential role for CD8+ T-cells in the initiation of the autoimmune response to beta-cells in the NOD mouse.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8314024     DOI: 10.2337/diab.43.3.500

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  75 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2K(d) that stimulates CD8 T cells in insulin-dependent diabetes mellitus.

Authors:  F Susan Wong; Antonis K Moustakas; Li Wen; George K Papadopoulos; Charles A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-09       Impact factor: 11.205

3.  A minor subset of Batf3-dependent antigen-presenting cells in islets of Langerhans is essential for the development of autoimmune diabetes.

Authors:  Stephen T Ferris; Javier A Carrero; James F Mohan; Boris Calderon; Kenneth M Murphy; Emil R Unanue
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

4.  Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood.

Authors:  Jacqueline D Trudeau; Carolyn Kelly-Smith; C Bruce Verchere; John F Elliott; Jan P Dutz; Diane T Finegood; Pere Santamaria; Rusung Tan
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 5.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

6.  DNA vaccination encoding glutamic acid decarboxylase can enhance insulitis and diabetes in correlation with a specific Th2/3 CD4 T cell response in non-obese diabetic mice.

Authors:  A Gauvrit; M Debailleul; A-T Vu; P Sai; J-M Bach
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

7.  Cutting edge: merocytic dendritic cells break T cell tolerance to beta cell antigens in nonobese diabetic mouse diabetes.

Authors:  Jonathan D Katz; Jennifer K Ondr; Robert J Opoka; Zacharias Garcia; Edith M Janssen
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

8.  Induction of insulitis by glutamic acid decarboxylase peptide-specific and HLA-DQ8-restricted CD4(+) T cells from human DQ transgenic mice.

Authors:  L Wen; F S Wong; L Burkly; M Altieri; C Mamalaki; D Kioussis; R A Flavell; R S Sherwin
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

9.  Pre-existing autoimmunity determines type 1 diabetes outcome after Flt3-ligand treatment.

Authors:  Tom L Van Belle; Therese Juntti; Jeanette Liao; Matthias G von Herrath
Journal:  J Autoimmun       Date:  2009-12-09       Impact factor: 7.094

10.  Perforin-independent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice.

Authors:  A Amrani; J Verdaguer; B Anderson; T Utsugi; S Bou; P Santamaria
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.